Skip to content

Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

Pilot Study to Assess Minimal Residual Disease on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04679285
Acronym
FERTILAM
Enrollment
9
Registered
2020-12-22
Start date
2021-04-26
Completion date
2022-09-04
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Keywords

Acute myeloid leukemia, Fertility preservation, Ovarian cryopreservation, Minimal residual disease

Brief summary

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation. This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

Interventions

None listed

Sponsors

Canceropôle Nord Ouest
CollaboratorOTHER
Saint-Louis Hospital, Paris, France
CollaboratorOTHER
University Hospital, Lille
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
2 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Patient diagnosed with AML * At least one molecular marker identified at AML diagnosis * Patients who undergo ovarian tissue cryopreservation for fertility preservation in complete remission, before hematopoietic stem cell transplantation.

Exclusion criteria

* Other diagnostic * No marker available at AML diagnosis * No bone marrow/ovarian fragment available at the time of complete remission

Design outcomes

Primary

MeasureTime frame
Percentage of patients without detectable MRD in ovarian tissueUp to 6 months

Secondary

MeasureTime frame
Percentage of patients with MRD detected in ovarian tissue and bone marrow.Up to 1 month

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026